Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 09/24 01:52:10 pm
46.525 EUR   +0.03%
09/23BAYER AG : Goldman Sachs remains its Buy rating
MD
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/22BAYER : Plans 2022 Launch For Vegetable Products Portfolio
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bayer to Buy Vividion Therapeutics

08/05/2021 | 01:45am EDT

By Maria Armental

Bayer AG is buying Vividion Therapeutics Inc. in a roughly $2 billion deal that would strengthen Bayer's drug discovery capabilities.

The German pharmaceuticals giant said it would pay $1.5 billion up front and up to $500 million if certain milestones are met.

San Diego-based Vividion, spun out from the Scripps Research Institute, had filed documents this year for an initial public offering. The company was formed around a technology platform for developing medications aimed at proteins thought to be "undruggable."

"Despite the hundreds of human proteins known to cause disease, about 10% of these targets are drugged by current therapies and the remaining targets, inaccessible to conventional chemistry, are perceived as pocketless or undruggable," the biotechnology company said in the IPO documents.

Vividion has initially focused on cancer and immune disorders. Its programs are in preclinical development, and the company currently generates revenue from collaboration agreements.

"Vividion's technology is the most advanced in the industry, and it has demonstrated its ability to identify drug candidates that can target challenging proteins," Stefan Oelrich, president of Bayer's pharmaceuticals division, said in a statement.

Under the terms of the agreement, Vividion will continue to operate as an independent organization, Bayer said.

The acquisition is expected to close in the third quarter.

Vividion's investors include ARCH Venture Partners, Versant Ventures and Cardinal Partners, according to the IPO documents.

Write to Maria Armental at maria.armental@wsj.com

(END) Dow Jones Newswires

08-05-21 0144ET

All news about BAYER AG
09/23BAYER AG : Goldman Sachs remains its Buy rating
MD
09/22PRESS RELEASE : Pfizer and BioNTech Expand -3-
DJ
09/22BAYER : Plans 2022 Launch For Vegetable Products Portfolio
MT
09/21PRESS RELEASE : Tele Columbus AG: New product portfolio and offers for autumn: PYUR confir..
DJ
09/20BAYER : Launches Study To Evaluate Nondiabetic Chronic Kidney Disease Treatment
MT
09/20BAYER : extends clinical development program for finerenone with Phase III study in patien..
PU
09/20PRESS RELEASE : Tele Columbus AG: M7 and PYUR extend partnership
DJ
09/20Bayer Extends Clinical Development Program for Kerendia
CI
09/20PRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
09/20WYLD : Signs Deal With Bayer Unit For Satellite System For Beehives
MT
More news
Analyst Recommendations on BAYER AG
More recommendations
Financials
Sales 2021 42 596 M 49 880 M 49 880 M
Net income 2021 860 M 1 007 M 1 007 M
Net Debt 2021 39 369 M 46 101 M 46 101 M
P/E ratio 2021 27,6x
Yield 2021 4,38%
Capitalization 45 693 M 53 504 M 53 506 M
EV / Sales 2021 2,00x
EV / Sales 2022 1,91x
Nbr of Employees 99 439
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 46,51 €
Average target price 62,45 €
Spread / Average Target 34,3%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG-3.42%53 623
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490